US Food and Drug Administration approvals seem to have waned from even the previous quarter when eight drugs with novel mechanisms were approved. Yet breakthrough therapy designation remains popular among drug developers and regulators as the designation moves into less trafficked areas. Two monoclonal antibodies for lowering cholesterol were neck and neck with PDUFA dates mere months apart, with one gaining approval already in the US, the other in Europe as this page was being prepared. Biosimilars are starting to take root as well.
Change history
06 October 2015
In the version of this article initially published, in the “Notable clinical trial results (2Q 2015)” table, clinical trial data for the drug Glembatumumab vedotin was said to be phase 3. It was phase 2, not phase 3, data. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: 2Q15. Nat Biotechnol 33, 795 (2015). https://doi.org/10.1038/nbt.3312
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3312
This article is cited by
-
Erratum: Drug pipeline: 2Q15
Nature Biotechnology (2015)
